EcoR1 Capital LLC Buys New Stake in Prelude Therapeutics Incorporated $PRLD

Posted by Brian Himes on Jul 28th, 2026

EcoR1 Capital LLC purchased a new stake in Prelude Therapeutics Incorporated (NASDAQ:PRLD – Free Report) during the first quarter, HoldingsChannel.com reports. The fund purchased 947,049 shares of the company’s stock, valued at approximately $3,239,000. Prelude Therapeutics comprises about 0.1% of EcoR1 Capital LLC’s investment portfolio, making the stock its 25th biggest holding.

Several other hedge funds have also bought and sold shares of the stock. AQR Capital Management LLC grew its position in shares of Prelude Therapeutics by 170.7% during the first quarter. AQR Capital Management LLC now owns 33,823 shares of the company’s stock valued at $26,000 after purchasing an additional 21,330 shares in the last quarter. Marshall Wace LLP purchased a new position in Prelude Therapeutics during the 2nd quarter valued at approximately $34,000. XTX Topco Ltd grew its holdings in Prelude Therapeutics by 72.4% during the 2nd quarter. XTX Topco Ltd now owns 42,573 shares of the company’s stock valued at $34,000 after buying an additional 17,873 shares in the last quarter. Shay Capital LLC bought a new stake in Prelude Therapeutics in the 2nd quarter worth approximately $61,000. Finally, Jane Street Group LLC purchased a new stake in shares of Prelude Therapeutics during the 2nd quarter worth approximately $74,000. Hedge funds and other institutional investors own 79.72% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. Zacks Research upgraded shares of Prelude Therapeutics to a “hold” rating in a research report on Tuesday, April 28th. Wall Street Zen upgraded shares of Prelude Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday. Weiss Ratings raised shares of Prelude Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 1st. D. Boral Capital started coverage on Prelude Therapeutics in a research report on Monday, May 4th. They issued a “buy” rating and a $9.00 price target for the company. Finally, HC Wainwright reissued a “buy” rating on shares of Prelude Therapeutics in a research note on Wednesday, July 15th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Prelude Therapeutics currently has a consensus rating of “Hold” and an average price target of $7.67.

Read Our Latest Stock Report on Prelude Therapeutics

Prelude Therapeutics Stock Up 1.6%

Shares of PRLD opened at $3.89 on Tuesday. The company has a market cap of $309.82 million, a PE ratio of -3.89 and a beta of 0.95. The business has a fifty day moving average of $4.30 and a 200 day moving average of $3.62. Prelude Therapeutics Incorporated has a 52-week low of $0.75 and a 52-week high of $5.69.

Prelude Therapeutics (NASDAQ:PRLD – Get Free Report) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.14. The firm had revenue of $4.58 million for the quarter, compared to analysts’ expectations of $4.58 million. As a group, research analysts anticipate that Prelude Therapeutics Incorporated will post -0.62 earnings per share for the current fiscal year.

Prelude Therapeutics Company Profile

(Free Report)

Prelude Therapeutics Incorporated is a clinical-stage precision medicine company focused on the discovery and development of small molecule therapies for genetically defined oncology targets. By leveraging a chemical biology approach, the company aims to deliver targeted treatments that address key drivers of cancer cell growth and survival. Prelude’s pipeline emphasizes novel inhibitors designed to engage molecular pathways validated by both preclinical and clinical evidence.

Among Prelude’s lead programs is PRT2527, a selective PI3K‐alpha/delta inhibitor in Phase 1 clinical trials for solid tumors harboring PIK3CA and other pathway mutations.